Efficacy and Safety of Beta-glucan Supplement in Chronic Obstructive Pulmonary Disease Patients

Efficacy and Safety of Beta-glucan Supplement in Chronic Obstructive Pulmonary Disease Patients

The objectives of this study are to evaluate Efficacy and safety of beta-glucan supplement in chronic obstructive pulmonary disease patients.

There are 72 patients in this study. They are randomly divided into 2 groups which are beta-glucan supplement group and placebo group. The supplement will be taken 1 capsule/day for 12 weeks. Forced expiratory volume in 1 second/Forced vital capacity, Modified Medical Research Council Dyspnea Score, Breathlessness, Cough, and Sputum Scale, 6 Minute Walk Test, Diffusing capacity for carbon monoxide, Tumor necrosis factor alpha, Interleukin-6, C-reactive protein, glutathione, aspartate transaminase, alanine transaminase, alkaline phosphatase, creatinine, and blood urea nitrogen are assessed before and after taking supplement 6 and 12 weeks.

Inclusion Criteria:

• Age more than 18 years
• Chronic Obstructive Pulmonary Disease with Forced expiratory volume in 1 second/Forced vital capacity after receiving bronchodilator medicine more than 70%
• No exacerbation and uncontrolled disease
• 10 pack-years smoking history 10 pack-years but stop smoking more than 1 years
• Willing to participate in this study

Exclusion Criteria:

• Respiratory infection in 4 weeks
• Lung cancer
• Liver disease or kidney disease
• Lung surgery history
• Take kung supplement in 2 weeks
• Take warfarin, clopidogrel, aspirin, or digoxin
• Allergic to beta-glucan, broccoli, or quercetin
• Cannot use Spirometry
• Pregnancy and lactation